Avecho Biotechnology Limited (AU:AVE)
ASX:AVE
Want to see AU:AVE full AI Analyst Report?
AVE Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume188.16K
Average Volume (3M)N/A
Market Cap
AU$53.63M
Enterprise ValueAU$33.92M
Total Cash (Recent Filing)AU$4.66M
Total Debt (Recent Filing)AU$14.47K
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,830,448,200
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)18.85
Price to Sales (P/S)23.75
P/FCF Ratio26.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary TPM PlatformAvecho's proprietary TPM formulation platform is a durable competitive asset: it can be licensed, used across pharmaceutical and nutraceutical products, and underpins multiple development pathways. A platform model supports recurring royalties, partnership leverage and scale without single-product dependence.
Positive Operating & Free Cash Flow (2025)Transitioning from multi-year cash burn to reported positive operating and free cash flow is a structurally meaningful improvement. Sustained positive cash generation enhances funding optionality, reduces dependency on dilutive financing, and provides resources to fund partnerships, commercialization or targeted R&D.
Revenue Rebound And Positive Gross ProfitAccelerating revenue with positive gross margins indicates core product formulations are monetizing and can scale. Durable top-line momentum plus gross profitability create a foundation for operating leverage as licensing or product sales expand, improving the path to sustained profitability over multiple quarters.
Bears Say
Persistent Operating And Net LossesOngoing sizable operating and net losses materially erode retained earnings and constrain internal funding for R&D and commercial expansion. If losses persist, the business will need recurring external capital or must sharply improve margins, creating execution and dilution risk over the medium term.
Shrinking Equity BaseA materially shrinking equity base reduces financial resilience and borrowing capacity, increasing vulnerability to adverse shocks. It also raises the likelihood of dilutive capital raises or tougher financing terms, which can impair long-term shareholder value and limit strategic flexibility.
Volatile Cash-flow HistoryHistoric volatility in cash flows undermines predictability for reinvestment and partner commitments. Reliance on lumpy licensing or milestone receipts can reverse the recent positive cash outcome, forcing reactive financing or cutbacks that impair long-term execution and make planning for commercialization more difficult.
Avecho Biotechnology Limited News
AVE FAQ
What was Avecho Biotechnology Limited’s price range in the past 12 months?
Avecho Biotechnology Limited lowest share price was <AU$0.01 and its highest was AU$0.01 in the past 12 months.
What is Avecho Biotechnology Limited’s market cap?
Avecho Biotechnology Limited’s market cap is AU$53.63M.
When is Avecho Biotechnology Limited’s upcoming earnings report date?
Avecho Biotechnology Limited’s upcoming earnings report date is Aug 31, 2026 which is in 73 days.
How were Avecho Biotechnology Limited’s earnings last quarter?
Avecho Biotechnology Limited released its earnings results on Feb 27, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Avecho Biotechnology Limited overvalued?
According to Wall Street analysts Avecho Biotechnology Limited’s price is currently Overvalued.
Does Avecho Biotechnology Limited pay dividends?
Avecho Biotechnology Limited does not currently pay dividends.
What is Avecho Biotechnology Limited’s EPS estimate?
Avecho Biotechnology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avecho Biotechnology Limited have?
Avecho Biotechnology Limited has 3,830,448,200 shares outstanding.
What happened to Avecho Biotechnology Limited’s price movement after its last earnings report?
Avecho Biotechnology Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Avecho Biotechnology Limited?
Currently, no hedge funds are holding shares in AU:AVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avecho Biotechnology Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-370.40%
Trailing 12-Months
Asset Growth
42.21%
Trailing 12-Months
Company Description
Avecho Biotechnology Limited
Avecho Biotechnology Limited, an Australian biotech firm established in Clayton in 1992 (originally known as Phosphagenics until May 2019), specializes in the creation, manufacturing, and distribution of products leveraging its proprietary Targeted Penetration Matrix (TPM) drug delivery platform. This innovative system finds applications across diverse sectors including pharmaceuticals, skincare, animal wellness, and nutritional products. The company's offerings include its foundational TPM and Vital ET products, designed for use in both drug delivery and cosmetic formulations. Furthermore, Avecho is actively developing enhanced pharmaceutical solutions such as TPM/Oxymorphone and TPM/Oxycodone. Its human health division focuses on delivering therapeutic agents via various methods, including gels, injectable solutions, and transdermal patches. In the animal health domain, Avecho provides non-antibiotic feed supplements aimed at boosting the health and feed efficiency of livestock. Demonstrating a commitment to research, the company has partnered with the Lambert Initiative at the University of Sydney to investigate the efficacy of topically applied cannabidiol in alleviating osteoarthritis symptoms. Avecho serves a broad international clientele, with a presence in Australia, Switzerland, India, and beyond.
Technical Analysis
Living Cell Technologies
―
Immuron Limited
―
Noxopharm Ltd.
―
Chimeric Therapeutics Ltd.
―
Memphasys Ltd
―
Options Prices
Currently, No data available
---